塞夫托实践研究:在多中心西班牙队列中使用塞夫托比普罗尔的现实数据
Carmen Hidalgo-Tenorio1, Inés Pitto-Robles1, Daniel Arnés García1
1Unit of Infectious Diseases, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitario de Granada (IBS-Granada), 18012 Granada, Spain.
Antibiotics (Basel, Switzerland)
|July 29, 2023
概括
塞夫托比普罗尔美多卡里尔 (Cefto-M) 是西班牙临床实践中使用的安全抗生素,主要用于老年患者的严重感染. 它显示有效性,但在呼吸机相关的肺炎和特定耐药细菌中死亡率更高.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 临床微生物学 临床微生物学
背景情况:
- 塞夫托比普罗尔是欧洲批准用于社区获得和医院结合性肺炎的第五代塞法索.
- 分析了它在西班牙临床实践中用于医院和门诊患者的肠外抗菌疗法 (OPAT) 感染的使用情况.
研究的目的:
- 为了分析西班牙患者在现实世界中使用 ceftobiprole medocaril (Cefto-M) 的情况.
- 评估其在各种感染类型中的安全性和有效性.
主要方法:
- 追溯性,观察性,多中心研究.
- 包括2021年9月至2022年12月期间接受治疗的249名患者.
- 分析感染类型,治疗方案和死亡率.
主要成果:
- 呼吸道感染 (55.8%) 和皮肤/软组织感染 (21.7%) 是最常见的.
- 在67.9%的病例中,Cefto-M被实证使用,通常作为单一疗法.
- 总体感染相关死亡率为11.2%,呼吸机相关肺炎 (40%) 和MRSA/伪omonas感染的比率更高.
结论:
- 在临床实践中,Cefto-M是一种安全的抗生素,经常用于呼吸道感染.
- 它主要用于重症感染的多病理患者的救援疗法.
- 影响死亡率的因素包括晚年,ICU入院和败血症/败血性休克.
相关概念视频
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...


